Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIVID-Japan: VEGF Trap-Eye in Japanese Subjects With DME
NCT01512966Phase 3Completed
- Sponsor
- Bayer
- Start
- Jan 2012
- Primary completion
- Sep 2013
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of aflibercept in diabetic macular edema (DME), sponsored by Bayer. Started Jan 2012; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT01512966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01512966.